Loading…

Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA

Recently, serum Golgi protein 73 (GP73) levels have been found to be elevated in patients with hepatocellu- lar carcinoma (HCC), and GP73 has been proposed as a novel marker for HCC. However, GP73 levels in patients remain controversial due to the specificity of the anti-GP73 antibody-based enzyme l...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biomedical research 2012-11, Vol.26 (6), p.467-473
Main Authors: Zhang, Aixia, Cao, Brian
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c469t-ac34b9b6cc4bd4aca33dd9213f7482dbc09be1e6fce52fdd3972ff48b28bbc933
cites
container_end_page 473
container_issue 6
container_start_page 467
container_title Journal of biomedical research
container_volume 26
creator Zhang, Aixia
Cao, Brian
description Recently, serum Golgi protein 73 (GP73) levels have been found to be elevated in patients with hepatocellu- lar carcinoma (HCC), and GP73 has been proposed as a novel marker for HCC. However, GP73 levels in patients remain controversial due to the specificity of the anti-GP73 antibody-based enzyme linked immunosorbent as- say (ELISA). Therefore, an anti-GP73 antibody with high specificity was highly demanded. In the present study, by hybridoma screening, we generated an anti-GP73 monoclonal antibody (mAb) designated as 6A2 using recom- binant GP73 protein produced by prokaryotic expression. The specificity of 6A2 was evaluated by Western blot- ting, immunohistochemistry and immunoprecipitation. The results showed that 6A2 recognized GP73 in both native and denatured forms. In addition, we have developed a sandwich ELISA using 6A2 and GP73 polyclonal antibody generated in New Zealand white rabbits according to standard procedures, and measured the serum GP73 level of patients using this assay. Our results showed that serum GP73 levels of HCC patients were significantly higher than those of healthy controls (P = 0.0036). Furthermore, for the first time, GP73 serum level was found to be elevated in patients with breast cancer compared with healthy controls (P = 0.0172).
doi_str_mv 10.7555/JBR.26.20120057
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3597050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>44293053</cqvip_id><els_id>S1674830112600670</els_id><sourcerecordid>1324385498</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-ac34b9b6cc4bd4aca33dd9213f7482dbc09be1e6fce52fdd3972ff48b28bbc933</originalsourceid><addsrcrecordid>eNp9kc1vFCEYxjlobNP27M2MNy-zZfiYGS4mtalrzSYaP84EXmAXMwMtsG3qXy_tbjd6kRBInvfhx5v3Qeh1hxcD5_z884dvC9IvCO4Ixnx4gY67fmDtSHF3hM5y_oXroqInbHyFjgjlnA1jf4z80gabVPExNCqYBjYqKSg2-d87Mbqq1118u_w60GaOIcIUg5qeRB3NQ-Niavw8b0PUUyzFh_UTK9fj3sOmuVpdf784RS-dmrI9298n6OfHqx-Xn9rVl-X15cWqBdaL0iqgTAvdAzBtmAJFqTGCdNQNbCRGAxbadrZ3YDlxxlAxEOfYqMmoNQhKT9D7Hfdmq2drwIaS1CRvkp9VepBReflvJfiNXMc7SbkYMMcV8G4PSPF2a3ORs89gp0kFG7dZdpQwOnImxmo931khxZyTdYdvOiwfc5E1F0l6-ZxLffHm7-4O_udEqkHsDLbO6M7bJDN4G8AanywUaaL_D_ztvp1NDOvbmsOBzxgRFHNK_wAk3Kt4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1324385498</pqid></control><display><type>article</type><title>Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA</title><source>PubMed Central</source><creator>Zhang, Aixia ; Cao, Brian</creator><creatorcontrib>Zhang, Aixia ; Cao, Brian</creatorcontrib><description>Recently, serum Golgi protein 73 (GP73) levels have been found to be elevated in patients with hepatocellu- lar carcinoma (HCC), and GP73 has been proposed as a novel marker for HCC. However, GP73 levels in patients remain controversial due to the specificity of the anti-GP73 antibody-based enzyme linked immunosorbent as- say (ELISA). Therefore, an anti-GP73 antibody with high specificity was highly demanded. In the present study, by hybridoma screening, we generated an anti-GP73 monoclonal antibody (mAb) designated as 6A2 using recom- binant GP73 protein produced by prokaryotic expression. The specificity of 6A2 was evaluated by Western blot- ting, immunohistochemistry and immunoprecipitation. The results showed that 6A2 recognized GP73 in both native and denatured forms. In addition, we have developed a sandwich ELISA using 6A2 and GP73 polyclonal antibody generated in New Zealand white rabbits according to standard procedures, and measured the serum GP73 level of patients using this assay. Our results showed that serum GP73 levels of HCC patients were significantly higher than those of healthy controls (P = 0.0036). Furthermore, for the first time, GP73 serum level was found to be elevated in patients with breast cancer compared with healthy controls (P = 0.0172).</description><identifier>ISSN: 1674-8301</identifier><identifier>DOI: 10.7555/JBR.26.20120057</identifier><identifier>PMID: 23554786</identifier><language>eng</language><publisher>China: Elsevier B.V</publisher><subject>GP73 ; hepatocellular carcinoma ; monoclonal antibody ; Research Paper ; sandwich ELISA ; Western blotting ; 免疫印迹 ; 单克隆抗体 ; 双抗体夹心ELISA ; 多克隆抗体 ; 肝细胞癌 ; 表征 ; 酶联免疫 ; 高尔基体</subject><ispartof>Journal of biomedical research, 2012-11, Vol.26 (6), p.467-473</ispartof><rights>2012 The Editorial Board of Journal of Biomedical Research</rights><rights>2012 by the Journal of Biomedical Research. All rights reserved. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-ac34b9b6cc4bd4aca33dd9213f7482dbc09be1e6fce52fdd3972ff48b28bbc933</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/85389A/85389A.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597050/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597050/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23554786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Aixia</creatorcontrib><creatorcontrib>Cao, Brian</creatorcontrib><title>Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA</title><title>Journal of biomedical research</title><addtitle>Journal of Biomedical Research</addtitle><description>Recently, serum Golgi protein 73 (GP73) levels have been found to be elevated in patients with hepatocellu- lar carcinoma (HCC), and GP73 has been proposed as a novel marker for HCC. However, GP73 levels in patients remain controversial due to the specificity of the anti-GP73 antibody-based enzyme linked immunosorbent as- say (ELISA). Therefore, an anti-GP73 antibody with high specificity was highly demanded. In the present study, by hybridoma screening, we generated an anti-GP73 monoclonal antibody (mAb) designated as 6A2 using recom- binant GP73 protein produced by prokaryotic expression. The specificity of 6A2 was evaluated by Western blot- ting, immunohistochemistry and immunoprecipitation. The results showed that 6A2 recognized GP73 in both native and denatured forms. In addition, we have developed a sandwich ELISA using 6A2 and GP73 polyclonal antibody generated in New Zealand white rabbits according to standard procedures, and measured the serum GP73 level of patients using this assay. Our results showed that serum GP73 levels of HCC patients were significantly higher than those of healthy controls (P = 0.0036). Furthermore, for the first time, GP73 serum level was found to be elevated in patients with breast cancer compared with healthy controls (P = 0.0172).</description><subject>GP73</subject><subject>hepatocellular carcinoma</subject><subject>monoclonal antibody</subject><subject>Research Paper</subject><subject>sandwich ELISA</subject><subject>Western blotting</subject><subject>免疫印迹</subject><subject>单克隆抗体</subject><subject>双抗体夹心ELISA</subject><subject>多克隆抗体</subject><subject>肝细胞癌</subject><subject>表征</subject><subject>酶联免疫</subject><subject>高尔基体</subject><issn>1674-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kc1vFCEYxjlobNP27M2MNy-zZfiYGS4mtalrzSYaP84EXmAXMwMtsG3qXy_tbjd6kRBInvfhx5v3Qeh1hxcD5_z884dvC9IvCO4Ixnx4gY67fmDtSHF3hM5y_oXroqInbHyFjgjlnA1jf4z80gabVPExNCqYBjYqKSg2-d87Mbqq1118u_w60GaOIcIUg5qeRB3NQ-Niavw8b0PUUyzFh_UTK9fj3sOmuVpdf784RS-dmrI9298n6OfHqx-Xn9rVl-X15cWqBdaL0iqgTAvdAzBtmAJFqTGCdNQNbCRGAxbadrZ3YDlxxlAxEOfYqMmoNQhKT9D7Hfdmq2drwIaS1CRvkp9VepBReflvJfiNXMc7SbkYMMcV8G4PSPF2a3ORs89gp0kFG7dZdpQwOnImxmo931khxZyTdYdvOiwfc5E1F0l6-ZxLffHm7-4O_udEqkHsDLbO6M7bJDN4G8AanywUaaL_D_ztvp1NDOvbmsOBzxgRFHNK_wAk3Kt4</recordid><startdate>201211</startdate><enddate>201211</enddate><creator>Zhang, Aixia</creator><creator>Cao, Brian</creator><general>Elsevier B.V</general><general>Editorial Department of Journal of Biomedical Research</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201211</creationdate><title>Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA</title><author>Zhang, Aixia ; Cao, Brian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-ac34b9b6cc4bd4aca33dd9213f7482dbc09be1e6fce52fdd3972ff48b28bbc933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>GP73</topic><topic>hepatocellular carcinoma</topic><topic>monoclonal antibody</topic><topic>Research Paper</topic><topic>sandwich ELISA</topic><topic>Western blotting</topic><topic>免疫印迹</topic><topic>单克隆抗体</topic><topic>双抗体夹心ELISA</topic><topic>多克隆抗体</topic><topic>肝细胞癌</topic><topic>表征</topic><topic>酶联免疫</topic><topic>高尔基体</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Aixia</creatorcontrib><creatorcontrib>Cao, Brian</creatorcontrib><collection>维普_期刊</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>维普中文期刊数据库</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of biomedical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Aixia</au><au>Cao, Brian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA</atitle><jtitle>Journal of biomedical research</jtitle><addtitle>Journal of Biomedical Research</addtitle><date>2012-11</date><risdate>2012</risdate><volume>26</volume><issue>6</issue><spage>467</spage><epage>473</epage><pages>467-473</pages><issn>1674-8301</issn><abstract>Recently, serum Golgi protein 73 (GP73) levels have been found to be elevated in patients with hepatocellu- lar carcinoma (HCC), and GP73 has been proposed as a novel marker for HCC. However, GP73 levels in patients remain controversial due to the specificity of the anti-GP73 antibody-based enzyme linked immunosorbent as- say (ELISA). Therefore, an anti-GP73 antibody with high specificity was highly demanded. In the present study, by hybridoma screening, we generated an anti-GP73 monoclonal antibody (mAb) designated as 6A2 using recom- binant GP73 protein produced by prokaryotic expression. The specificity of 6A2 was evaluated by Western blot- ting, immunohistochemistry and immunoprecipitation. The results showed that 6A2 recognized GP73 in both native and denatured forms. In addition, we have developed a sandwich ELISA using 6A2 and GP73 polyclonal antibody generated in New Zealand white rabbits according to standard procedures, and measured the serum GP73 level of patients using this assay. Our results showed that serum GP73 levels of HCC patients were significantly higher than those of healthy controls (P = 0.0036). Furthermore, for the first time, GP73 serum level was found to be elevated in patients with breast cancer compared with healthy controls (P = 0.0172).</abstract><cop>China</cop><pub>Elsevier B.V</pub><pmid>23554786</pmid><doi>10.7555/JBR.26.20120057</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1674-8301
ispartof Journal of biomedical research, 2012-11, Vol.26 (6), p.467-473
issn 1674-8301
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3597050
source PubMed Central
subjects GP73
hepatocellular carcinoma
monoclonal antibody
Research Paper
sandwich ELISA
Western blotting
免疫印迹
单克隆抗体
双抗体夹心ELISA
多克隆抗体
肝细胞癌
表征
酶联免疫
高尔基体
title Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T21%3A27%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Generation%20and%20characterization%20of%20an%20anti-GP73%20monoclonal%20antibody%20for%20immunoblotting%20and%20sandwich%20ELISA&rft.jtitle=Journal%20of%20biomedical%20research&rft.au=Zhang,%20Aixia&rft.date=2012-11&rft.volume=26&rft.issue=6&rft.spage=467&rft.epage=473&rft.pages=467-473&rft.issn=1674-8301&rft_id=info:doi/10.7555/JBR.26.20120057&rft_dat=%3Cproquest_pubme%3E1324385498%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c469t-ac34b9b6cc4bd4aca33dd9213f7482dbc09be1e6fce52fdd3972ff48b28bbc933%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1324385498&rft_id=info:pmid/23554786&rft_cqvip_id=44293053&rfr_iscdi=true